查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1738592

全球大容量肠外产品（LVP）市场规模、应用、最终用户、区域范围和预测

Global Large Volume Parenteral (LVP) Market Size By Volume (100 ml - 250 ml, 250 ml - 500 ml), By Application (Therapeutic Injections, Fluid Balance Injections), By End-User (Hospitals, Medical Centres), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

大容量肠外给药（LVP）的市场规模与预测

2024 年大容量肠外给药 (LVP) 市场规模价值 130.2 亿美元，预计到 2032 年将达到 257.2 亿美元，在 2026-2032 年预测期内的复合年增长率为 8.88%。

患者对更安全、更快捷、更有效的给药方法的需求日益增长，推动了全球大剂量肠外产品 (LVP) 市场的成长。如今，患者也更倾向于单剂量注射疫苗和药物来治疗慢性疾病，这也促进了市场的成长。 《全球大剂量肠外产品 (LVP) 市场报告》对市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的主要因素。

定义全球大容量肠外产品（LVP）市场

肠外製剂是指注射剂，为无菌产品，设计用于透过注射、输注或植入体内给药。大容量肠外製剂 (LVP) 是指容量超过 100 毫升的单位剂量容器，最终透过加热灭菌。此类肠外製剂包括以 100 毫升或更大容量的袋装或瓶装形式出售的输液。当需要更大剂量时，它们会以散装形式包装。肠外製剂通常为无菌固态或无热原液体製剂，内含一种或多种活性成分，并装于单剂量或多剂量容器中。

肠外给药是透过输注、植入或註射的方式进入体内。它们不受物理、化学和生物污染。随着生物技术领域的发展，肠外给药的药物数量也不断增加，因为当口服给药不合适时，肠外给药是最佳选择。肠外给药能够提供最大的疗效和生物利用度，因此通常比口服给药更受青睐。

全球大容量肠外给药（LVP）市场概况

健康相关问题的增加导致住院人数增加，从而增加了对更快、更安全、更有效的药物给药的需求，这推动了全球大容量肠外产品 (LVP) 市场的成长。外科手术的数量不断增加，因此对更快捷的给药途径的需求也随之增加，人们越来越偏好单剂量给药疫苗和药物。

此外，随着需求的增长，本地製造也在不断增长，预计将推动市场发展。由于大多数药物直接被吸收进入血液循环，绕过胃肠道，因此能够透过提供准确的剂量来帮助给药。患有慢性病和其他文明病的患者越来越多，并因此住院治疗。

单剂量神经系统疾病、肿瘤和糖尿病的引入为全球大剂量肠外给药 (LVP) 市场创造了丰厚的机会。此外，患者现在更倾向于使用单剂量疫苗和药物来治疗慢性疾病，这推动了全球大剂量肠外给药 (LVP) 市场的成长。需求的不断增长加上生产延误阻碍了市场的成长。此外，LVP 的品质问题和其他生产问题导致肠外给药短缺，从而抑制了市场的发展。

全球大容量肠外注射 (LVP) 市场根据容量、应用、最终用户和地区进行细分。

大容量肠外注射 (LVP) 市场（按数量）

  • 100～250ml
  • 250～500ml
  • 500～1,000ml
  • 1,000～2,000ml
  • 2,000毫升或以上

容量分为两个部分：100-250ml、250-500ml、500-1000ml、1000-2000ml 和 2000ml 以上。 2022 年，250ml 至 500ml 之间的大容量肠外给药 (LVP) 部分占据了市场主导地位。大容量肠外给药 (LVP)，通常称为 LVP，是经由肠外给药的 250ml 或以上的无菌製剂。例如，最受欢迎的 LVP 是由标准/基础溶液製成的静脉注射溶液，例如 0.9% 氯化钠、5% 葡萄糖生理食盐水 (D5NS)、5% 葡萄糖水溶液 (D5W) 和乳酸林格氏液 (LR)。 LVP 是用 100ml 或以上（250ml、500ml、1L）的袋或瓶输送的静脉注射溶液。

大容量肠外药物（LVP）市场（依应用）

  • 治疗性注射
  • 液体平衡注射
  • 营养注射

根据应用，营养注射剂可细分为治疗性注射剂、体液平衡注射剂和营养性注射剂。根据应用，营养注射剂预计将在预测期内占据全球大容量肠外产品 (LVP) 市场的主导地位。这是由于老年人和儿童族群的使用日益增多，以及溃疡性大肠炎和癌症等慢性疾病的治疗需求。这些患者需要持续的营养供应系统来弥补营养不足，这为营养注射剂市场的发展奠定了基础。

大容量肠外注射 (LVP) 市场（依最终用户划分）

  • 医院
  • 医疗中心
  • 其他的

根据最终用户，市场细分为医院、医疗中心和其他。全球大容量肠外给药 (LVP) 市场主要由医院和医疗机构主导。

大容量肠外药物（LVP）市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
  • 根据地区划分，全球大容量肠外给药 (LVP) 市场分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。由于公共和私人机构对医疗保健研究的大量投入、技术先进的医疗设备以及监管机构、行业和大学之间的密切伙伴关係，北美在整个预测期内一直引领全球市场。
  • 此外，优惠的付款规定也推动了住院人数的增加，预计这将推动该领域的使用率。对于肠外营养而言，报销前景光明：在美国，医疗保险（Medicare）最多可报销患者与肠外和经肠营养相关的费用的80%，包括医疗用品、医生就诊和其他相关医疗保健服务的费用。

主要参与企业

全球大容量肠外产品 (LVP) 市场研究报告提供了针对全球市场的宝贵见解，主要企业包括 B. Braun Melsungen AG、Fresenius Kabi AG、BML Parenteral Drugs、辉瑞公司、大冢製药、科伦製药、库克製药、Patheon、BAGax Healthcare、西南製药、Beximco Corporation 和 Bter Healthcare)。

我们的市场分析还包括关于这些主要企业的专门部分，我们的分析师在其中提供对所有主要企业的财务报表的见解以及产品基准评效和 SWOT 分析。竞争格局部分还包括上述全球参与企业的关键发展策略、市场占有率和市场排名分析。

  • Ace矩阵分析
  • 本报告提供的 Ace Matrix 将根据服务特点、创新、扩张、服务创新、行业覆盖范围、行业影响力、成长蓝图等各种因素对参与此行业的主要主要企业进行排名，从而帮助您了解这些公司的表现。根据这些因素，这些主要企业被分为四类：活跃型、前沿型、新兴型和创新型。
  • 大容量肠外药物（LVP）市场的 Ace 矩阵分析
  • 市场吸引力
  • 提供的市场吸引力图表进一步帮助我们了解引领全球大容量肠外製剂 (LVP) 市场的主要地区。我们涵盖了推动特定地区产业成长的关键影响因素。
  • 大容量肠外药物（LVP）市场的地理标誌
  • 波特五力模型
  • 波特五力模型是一个框架，它为理解每个产业的竞争对手行为和策略定位提供了蓝图。波特五力模型可用于评估全球大容量肠外产品 (LVP) 市场的竞争格局，衡量特定细分市场的吸引力，并评估投资潜力。

目录

第 1 章全球大容量肠外产品 (LVP) 市场简介

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第 2 章 已验证的市场研究调查方法

  • 资料探勘
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 业界专家的重要见解
  • 资料来源

第三章执行摘要

  • 市场概览
  • 生态测绘
  • 绝对的商机
  • 市场吸引力
  • 全球大容量肠外产品（LVP）市场区域分析
  • 全球大容量肠外产品（LVP）市场规模（百万美元）
  • 全球大容量肠外产品（LVP）市场应用（百万美元）
  • 全球大容量肠外产品（LVP）市场（以最终用户划分）（百万美元）
  • 未来市场机会
  • 全球市场区隔
  • 产品生命线

第四章 大容量肠外药物（LVP）的全球市场展望

  • 大容量注射（LVP）的全球发展
  • 驱动程式
    • 司机1
    • 司机2
  • 限制因素
    • 约束因素 1
    • 限制因素2
  • 机会
    • 机会1
    • 机会2
  • 波特五力模型
  • 价值链分析
  • 定价分析
  • 宏观经济分析

5. 全球大容量肠外产品（LVP）市场规模

  • 概述
  • 100～250 ml
  • 250～500 ml
  • 500～1,000 ml
  • 1,000～2,000ml
  • 2,000毫升或以上

6. 全球大容量肠外产品（LVP）市场应用

  • 概述
  • 治疗注射
  • 液体平衡注射
  • 营养注射

7. 全球大容量肠外产品（LVP）市场（依最终用户）

  • 概述
  • 医院
  • 医疗中心
  • 其他的

8. 全球大容量肠外产品（LVP）市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9. 全球大容量肠外产品（LVP）市场的竞争格局

  • 概述
  • 各公司市场排名
  • 公司地理分布
  • 各公司的工业足迹
  • ACE矩阵

第十章 公司简介

  • B. Braun Melsungen AG
  • Fresenius Kabi AG
  • BML Parenteral Drugs
  • Pfizer, Inc
  • Otsuka Pharmaceutical
  • Kelun Pharma
  • Cook Pharma
  • Patheon
  • BAG Healthcare
  • Southwest Pharmaceuticals
  • Baxter Healthcare Corporation

第 11 章 已验证的市场情报

  • 关于已验证的市场情报
  • 动态资料视觉化
简介目录
Product Code: 62219

Large Volume Parenteral (LVP) Market Size And Forecast

Large Volume Parenteral (LVP) Market size was valued at USD 13.02 Billion in 2024 and is projected to reach USD 25.72 Billion by 2032, growing at a CAGR of 8.88% from 2026 to 2032.

The rising demand for safer, faster, and more effective methods for drug administration in patients leads to drive the market growth of the Global Large Volume Parenteral (LVP) Market. Also, patients now preferring to take administration for a single dose of vaccines or drugs to treat chronic diseases propels the market growth. The Global Large Volume Parenteral (LVP) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Large Volume Parenteral (LVP) Market Definition

Parenterals are injectable preparations, sterile products which are intended for administration by way of injection, infusion, or implantation into the body. A large volume parenteral (LVP) is a unit dose container of greater than 100ml which is terminally sterilized by heat. These parenteral are included with intravenous solutions which are sold to be in bags or bottles containing 100ml or of greater sizes. If a large quantity is required then it is packaged in large volumes. When preparation of parental takes place parentals are sterile, solid dosage form or pyrogen-free liquids, which contain one or more active ingredients boxed in single or multi-dose containers.

Parenterals are meant to be administered by way of infusion, transplantation, or injection in the body. These are free of physical, chemical, and biological contamination. As the biotechnology field is developing there is a development in a certain number of drugs administered parenterally because the parenteral route is the best, when the oral route is not suitable. Maximum efficacy and bio-availability are provided by Parenterals and are preferred over oral dosages in a vast number of instances.

Global Large Volume Parenteral (LVP) Market Overview

The increase in health-related issues leads to the increasing hospitalization rate of people and due to this, there is a rise in demand for faster, safer, and effective administration of drugs which drives the growth of the Global Large Volume Parenteral (LVP) Market. Surgeries are increasing at a higher pace and because of this, there is an increase in the need for a faster route of drug administration and a growing preference for single-dose administration of vaccines and drugs.

Also, as the demand is increasing there is an increase in the local manufacturing which is expected to drive the market. The parental route helps in administering by providing an accurate dose of medication because the majority of the drug is directly absorbed in circulation, bypassing the gastrointestinal tract Parental route helps in administering and also drives the market growth. Patients with chronic and other lifestyle-related diseases are increasing and because of it, they were hospitalized.

The introduction of single-dosage nervous system disorders, oncology, and diabetes creates lucrative opportunities for the Global Large Volume Parenteral (LVP) Market. Also, patients are now preferring single-dose administration of vaccines and drugs to treat chronic diseases which drives the growth of the Global Large Volume Parenteral (LVP) Market. Increased demand in combination with manufacturing delays hampers the growth of the market. Also, LVPs quality issues and other manufacturing problems will result in a shortage of parenteral will restrain the market.

The Global Large Volume Parenteral (LVP) Market is segmented on the basis of Volume, Application, End-User, And Geography.

Large Volume Parenteral (LVP) Market, By Volume

100 ml - 250 ml

250 ml - 500 ml

500 ml - 1000 ml

1000 ml - 2000 ml

2000 ml and more

Based on Volume, The market is bifurcated into 100 ml - 250 ml, 250 ml - 500 ml, 500 ml - 1000 ml, 1000 ml - 2000 ml, and 2000 ml and more. In 2022, the 250 ml - 500 ml large volume parenteral (LVP) segment dominated the market. Large Volume Parenteral (LVP), often known as LVPs, are sterile preparations of 250 mL or higher that are delivered parenterally. For example, the most popular LVPs are IV solutions made from a standard/base solution, like 0.9% sodium chloride, dextrose 5% in normal saline (D5NS), dextrose 5% in water (D5W), and Lactate Ringer (L.R.) solution. LVPs are intravenous solutions offered in bags or bottles holding 100 mL or more (250 mL, 500 mL, 1 L).

Large Volume Parenteral (LVP) Market, By Application

  • Therapeutic Injections
  • Fluid Balance Injections
  • Nutritious Injections

Based on Application, The market is bifurcated into Therapeutic Injections, Fluid Balance Injections, and Nutritious Injections. The nutritious injections by application segment are expected to dominate the Global Large Volume Parenteral (LVP) Market during the forecast period, owing to growing applications in the geriatric and pediatric populations, as well as its requirement in the management of chronic diseases such as ulcerative colitis and cancer. These patients require a continuous feeding system to compensate for nutritional inadequacies, paving the way for the segment.

Large Volume Parenteral (LVP) Market, By End-User

  • Hospitals
  • Medical Centers
  • Others

Based on End-User, The market is bifurcated into Hospitals, Medical Centres, and Others. Hospitals and healthcare facilities will dominate the overall market for the Global Large Volume Parenteral (LVP) Market.

Large Volume Parenteral (LVP) Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  • On the basis of Regional Analysis, The Global Large Volume Parenteral (LVP) Market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America led the global market throughout the projection period due to its significant investment in healthcare research by public and private organizations, its technologically cutting-edge medical equipment, and its regulatory agencies and industry's close partnerships with universities.
  • Additionally, favorable payment rules have increased hospital admissions, which is expected to enhance utilization rates in this area. For IV nutrition, the reimbursement picture is encouraging. Medicare provides patients with coverage for up to 80% of the costs associated with parenteral and enteral nourishment in the US, including the cost of medical supplies, doctor visits, and other related healthcare services.

Key Players

The "Global Large Volume Parenteral (LVP) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are B. Braun Melsungen AG, Fresenius Kabi AG, BML Parenteral Drugs, Pfizer, Inc, Otsuka Pharmaceutical, Kelun Pharma, Cook Pharma, Patheon, BAG Healthcare, Southwest Pharmaceuticals, Beximco Pharma, Baxter Healthcare Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Ace Matrix Analysis of Large Volume Parenteral (LVP) Market
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Large Volume Parenteral (LVP) Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Geographical Representation of Large Volume Parenteral (LVP) Market
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in the Global Large Volume Parenteral (LVP) Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Large Volume Parenteral (LVP) Market Geographical Analysis (CAGR %)
  • 3.6 Global Large Volume Parenteral (LVP) Market, By Volume (USD Million)
  • 3.7 Global Large Volume Parenteral (LVP) Market, By Application (USD Million)
  • 3.8 Global Large Volume Parenteral (LVP) Market, By End User (USD Million)
  • 3.9 Future Market Opportunities
  • 3.10 Global Market Split
  • 3.11 Product Life Line

4 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET OUTLOOK

  • 4.1 Global Large Volume Parenteral (LVP) Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY VOLUME

  • 5.1 Overview
  • 5.2100 ml - 250 ml
  • 5.3 250 ml - 500 ml
  • 5.4 500 ml -1000 ml
  • 5.51000 ml - 2000 ml
  • 5.6 2000 ml and more

6 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Therapeutic Injections
  • 6.3 Fluid Balance Injections
  • 6.4 Nutritious Injections

7 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Medical Centers
  • 7.4 Others

8 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Developments
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 B. Braun Melsungen AG
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Fresenius Kabi AG
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 BML Parenteral Drugs
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Pfizer, Inc
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Otsuka Pharmaceutical
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Kelun Pharma
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 Cook Pharma
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 Patheon
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.9 BAG Healthcare
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 Southwest Pharmaceuticals
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis
  • 10.11 Baxter Healthcare Corporation.
    • 10.11.1 Company Overview
    • 10.11.2 Company Insights
    • 10.11.3 Business Breakdown
    • 10.11.4 Product Benchmarking
    • 10.11.5 Key Developments
    • 10.11.6 Winning Imperatives
    • 10.11.7 Current Focus & Strategies
    • 10.11.8 Threat from Competition
    • 10.11.9 SWOT Analysis

11 VERIFIED MARKET INTELLIGENCE

  • 11.1 About Verified Market Intelligence
  • 11.2 Dynamic Data Visualization